Search results for "B-Cell"

showing 10 items of 279 documents

Evaluation of the impact of therapeutic management on the survival and quality of life of patients with follicular lymphoma or diffuse large B cell l…

2014

In France, hematologic malignancies, which are the sixthmost common cancers, are amajor public healthproblem. This work aimed to study the impact of the therapeutic management on survival and healt-relatedquality of life (HRQoL) in patients with these hematologic malignancies. The first objective of this work is topresent an overview of the epidemiology of lymphoid malignancies with a study of changes in the incidenceand net survival in the Côte d’Or department between 1980 and 2009. The incidence, which has increased since1980, seems to have stabilized since the 2000s for some entities, including follicular lymphoma (FL) and diffuselarge B-cell lymphoma (DLBCL). Overall, we observed an imp…

Propensity scoreSurvie netteQualité de vie relative à la santéHealth-related quality of lifeIncidenceHémopathie lymphoïdeDiffuse large B-cell lymphomaLymphome folliculaireLymphome B diffus à grandes cellulesFollicular lymphomaNet survivalSurvie globale[SDV.SPEE] Life Sciences [q-bio]/Santé publique et épidémiologieScore de propensionHematologic malignanciesOverall survivalRituximab
researchProduct

Proteasomes shape the repertoire of T cells participating in antigen-specific immune responses

2006

Differences in the cleavage specificities of constitutive proteasomes and immunoproteasomes significantly affect the generation of MHC class I ligands and therefore the activation of CD8-positive T cells. Based on these findings, we investigated whether proteasomal specificity also influences CD8-positive T cells during thymic selection by peptides derived from self proteins. We find that one of the self peptides responsible for positive selection of ovalbumin-specific OT-1 T cells, which is derived from the f-actin capping protein (Cpalpha1), is efficiently generated only by immunoproteasomes. Furthermore, OT-1 mice backcrossed onto low molecular mass protein 7 (LMP7)-deficient mice show a…

Proteasome Endopeptidase ComplexOvalbuminActin Capping ProteinsT-LymphocytesMolecular Sequence DataReceptors Antigen B-CellThymus GlandBiologyEpitopeInterleukin 21MiceImmune systemAntigenMultienzyme ComplexesMHC class ICytotoxic T cellT cell repertoire; selectionAnimalsIL-2 receptorAmino Acid SequenceAntigensSelection GeneticBone Marrow TransplantationMice KnockoutMultidisciplinaryBiological SciencesMolecular biologyPeptide FragmentsMice Inbred C57BLCTL*biology.proteinLymph Nodes
researchProduct

Expression of B-Cell Activating Factor Enhances Protective Immunity of a Vaccine against Pseudomonas aeruginosa

2009

ABSTRACT B-cell activating factor (BAFF), a member of the TNF family, is a potent cytokine with stimulatory effects on B and T cells. To evaluate the potential of transient overexpression of BAFF to enhance vaccine immunogenicity, a replication-deficient adenovirus expressing full-length murine BAFF (AdBAFF) was tested in a mouse vaccine model against Pseudomonas aeruginosa . When coadministered with heat-killed P. aeruginosa , AdBAFF mediated a significant increase in anti- P. aeruginosa- specific serum and lung mucosal antibodies and resulted in improved protection against a lethal respiratory challenge with P. aeruginosa . This effect was independent of the site of administration of AdBA…

Pseudomonas Vaccinesmedicine.medical_treatmentGenetic VectorsImmunologyBiologymedicine.disease_causeMicrobiologyAdenoviridaeMicrobiologyMiceImmune systemAdjuvants ImmunologicImmunityB-Cell Activating FactorPneumonia BacterialmedicineAnimalsB-cell activating factorImmunity MucosalPseudomonas aeruginosaAntibodies BacterialSurvival AnalysisMice Inbred C57BLInfectious DiseasesCytokineVaccines InactivatedImmunizationMicrobial Immunity and VaccinesPseudomonas aeruginosaImmunologybiology.proteinFemaleParasitologyAntibodyAdjuvantInfection and Immunity
researchProduct

Patterns of oncogene co-expression at single cell resolution in cancer influence survival

2020

AbstractBackgroundCancers often overexpress multiple clinically relevant oncogenes. However, it is not known if multiple oncogenes within a cancer combine uniquely in specific cellular sub-populations to influence clinical outcome. We studied this phenomenon using the prognostically relevant oncogenes MYC, BCL2 and BCL6 in Diffuse Large B-Cell Lymphoma (DLBCL).MethodsQuantitative multispectral imaging simultaneously measured oncogene co-expression at single-cell resolution in reactive lymphoid tissue (n=12) and four independent cohorts (n=409) of DLBCL. Mathematically derived co-expression phenotypes were evaluated in DLBCLs with immunohistochemistry (n=316) and eight DLBCL cohorts with gen…

Quantitative immunohistochemistryCellBiologyBCL6medicine.diseasemedicine.anatomical_structureimmune system diseaseshemic and lymphatic diseasesGene expressionCo localisationmedicineCancer researchImmunohistochemistryneoplasmsDiffuse large B-cell lymphomaPatient stratification
researchProduct

Real-World Evidence of Tisagenlecleucel for the Treatment of Relapsed or Refractory Large B-Cell Lymphoma

2020

Introduction Tisagenlecleucel (tisa-cel) is a second generation, CD19-targeted Chimeric Antigen Receptor (CAR) T-cell therapy for relapsed or refractory (R/R) large B-cell lymphoma (LBCL). The pivotal phase 2 trial JULIET included 93 patients and reported an overall response rate (ORR) of 52% and a complete response rate of 40% among treated patients. However, very little is known regarding its safety and efficacy in the commercial or real-world setting as well as from an intention-to-treat perspective. In our study, we report clinical outcomes of patients with R/R LBCL treated with commercial tisa-cel in 10 Spanish institutions. Methods Data were collected retrospectively from all consecut…

Refractorybusiness.industryImmunologymedicineCancer researchCell BiologyHematologyB-cell lymphomamedicine.diseasebusinessReal world evidenceBiochemistryBlood
researchProduct

Toll-like receptors and autoimmunity

2008

The understanding of autoimmune diseases experienced an impressive boost since the Toll-like receptors (TLRs) have been identified as possible key players in autoimmune pathophysiology. Although these receptors recognize a variety of structures derived from viruses, bacteria and fungi leading to subsequent initiation of the relevant immune responses recent data support the idea that TLRs are crucial in the induction and perpetuation of certain autoimmune diseases, especially the systemic lupus erythematosus (SLE). In this review we will summarize recent data on involvement of TLRs in the development of autoimmune diseases. This review will focus on TLRs 7, 8 and 9 which were originally iden…

Regulation of gene expressionToll-Like ReceptorsImmunologyReceptors Antigen B-CellRNAAutoimmunityContext (language use)Dendritic CellsBiologymedicine.disease_causeAutoimmunitychemistry.chemical_compoundImmune systemGene Expression RegulationAntigenchemistryImmunologymedicineHumansImmunology and AllergyReceptorDNAAutoimmunity Reviews
researchProduct

Genome-wide association study identifies multiple risk loci for chronic lymphocytic leukemia

2013

Genome-wide association studies (GWAS) have previously identified 13 loci associated with risk of chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL). To identify additional CLL susceptibility loci, we conducted the largest meta-analysis for CLL thus far, including four GWAS with a total of 3,100 individuals with CLL (cases) and 7,667 controls. In the meta-analysis, we identified ten independent associated SNPs in nine new loci at 10q23.31 (ACTA2 or FAS (ACTA2/FAS), P = 1.22 × 10-14), 18q21.33 (BCL2, P = 7.76 × 10-11), 11p15.5 (C11orf21, P = 2.15 × 10 -10), 4q25 (LEF1, P = 4.24 × 10-10), 2q33.1 (CASP10 or CASP8 (CASP10/CASP8), P = 2.50 × 10-9), 9p21.3 (CDKN2B-AS1, P = 1.27 × 10…

RiskLinkage disequilibriumChronic lymphocytic leukemiaSingle-nucleotide polymorphismLocus (genetics)Genome-wide association studyBiologyPolymorphism Single NucleotideLinkage DisequilibriumArticleGeneticsmedicineHumansGenetic Predisposition to DiseaseLeucèmia limfocítica crònicaGenome-wide association studies (GWAS)B-cell lymphomachronic lymphocytic leukemia or small lymphocytic lymphoma (CLL)Genetic associationRecombination GeneticGeneticsGenomicsmedicine.diseaseLeukemia Lymphocytic Chronic B-CellGenòmicaLeukemiaGenetic LociCase-Control StudiesChromosomes Human Pair 2Chronic lymphocytic leukemiaGenome-Wide Association Study
researchProduct

Chronic lymphocytic leukemia nurse-like cells express hepatocyte growth factor receptor (c-MET) and indoleamine 2,3-dioxygenase and display features …

2014

Hepatocyte growth factor, produced by stromal and follicular dendritic cells, and present at high concentrations in the sera of patients with chronic lymphocytic leukemia, prolongs the survival of leukemic B cells by interacting with their receptor, c-MET. It is, however, unknown whether hepatocyte growth factor influences microenvironmental cells, such as nurse-like cells, which deliver survival signals to the leukemic clone. We evaluated the expression of c-MET on nurse-like cells and monocytes from patients with chronic lymphocytic leukemia and searched for phenotypic/functional features supposed to be influenced by the hepatocyte growth factor/c-MET interaction. c-MET is expressed at hi…

STAT3 Transcription FactorC-MetStromal cellmedicine.medical_treatmentGene ExpressionBiologyMonocyteschemistry.chemical_compoundT-Lymphocyte SubsetsmedicineHumansIndoleamine-Pyrrole 23-DioxygenaseGrowth factor receptor inhibitorPhosphorylationIndoleamine 23-dioxygenaseCells CulturedFollicular dendritic cellsMacrophagesGrowth factorArticlesHematologyProto-Oncogene Proteins c-metLeukemia Lymphocytic Chronic B-CellCoculture TechniquesInterleukin-10C-MET; INDOLEAMINE 23-DIOXYGENASEchronic lymphocytic leukemia hepatocyte growth factor c-MET nurse-like cellshepatocyte growth factornurse-like cellschemistryHepatocyte Growth Factor ReceptorCancer researchchronic lymphocytic leukemiaHepatocyte growth factorC-METINDOLEAMINE 23-DIOXYGENASEmedicine.drugHaematologica
researchProduct

Synthetic lethal metabolic targeting of cellular senescence in cancer therapy.

2013

Activated oncogenes and anticancer chemotherapy induce cellular senescence, a terminal growth arrest of viable cells characterized by S-phase entry-blocking histone 3 lysine 9 trimethylation (H3K9me3). Although therapy-induced senescence (TIS) improves long-term outcomes, potentially harmful properties of senescent tumour cells make their quantitative elimination a therapeutic priority. Here we use the Eµ-myc transgenic mouse lymphoma model in which TIS depends on the H3K9 histone methyltransferase Suv39h1 to show the mechanism and therapeutic exploitation of senescence-related metabolic reprogramming in vitro and in vivo. After senescence-inducing chemotherapy, TIS-competent lymphomas but …

SenescenceMaleLymphoma B-CellTransgeneApoptosisMice TransgenicMiceUbiquitinStress PhysiologicalAutophagyAnimalsCaspase 12Cellular SenescenceMultidisciplinarybiologyCaspase 3Endoplasmic reticulumAutophagyEndoplasmic Reticulum StressSurvival RateDisease Models AnimalHistoneGlucoseBiochemistryHistone methyltransferaseProteolysisUnfolded protein responsebiology.proteinCancer researchFemaleNature
researchProduct

Functional characterisation of the first HSP110 inhibitors.

2023

Heat shock proteins are molecular chaperones highly expressed in haematological malignancies. My laboratory has shown that the heat shock protein HSP110 is a new and important therapeutic target In colorectal cancer and in non-Hodgkin's lymphoma. As there were no existing inhibitors of HSP110, a screening strategy of a chemical library was carried out and allowed the identification of two molecules capable of specifically inhibiting the chaperone activity of HSP110. My thesis objective was to characterise and functionally validate these newly identified molecules in diffuse large cell B lymphomas. I have shown that one of these molecules limits the interaction of HSP110 with the SYK signall…

Signaling pathwaysVoies de signalisationHeat Shock Protein[SDV.BBM.BM] Life Sciences [q-bio]/Biochemistry Molecular Biology/Molecular biologyProtéine de choc thermiqueTargeted therapyActivated B Cell Diffuse Large B-Cell LymphomaLymphome B Diffus à Grandes Cellules de Type ActivéLymphome B Primitif du MédiastinCancer treatment[SDV.BBM.BC] Life Sciences [q-bio]/Biochemistry Molecular Biology/Biochemistry [q-bio.BM]Primary Mediastinal B cell LymphomaThérapie cibléeTraitements du cancer
researchProduct